HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NA

HC Wainwright reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a report published on Friday, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered shares of Arbutus Biopharma from a buy rating to a hold rating in a research note on […]

Related Keywords

United States , American , , York Mellon Corp , American International Group Inc , Arbutus Biopharma Corporation , Jpmorgan Chase Co , Moneta Group Investment Advisors , Arbutus Biopharma , Free Report , Biopharma Trading Down , New York Mellon Corp , Street Group , Group Investment Advisors , International Group , Get Free Report , Biopharma Corporation , Arbutus Biopharma Daily , Nasdaq Abus , Mabus , Medical , Reiterated Rating , Hc Wainwright ,